A novel compound able to inhibit JAK is disclosed,(see formula VIa)This compound may be prepared as a pharmaceutical composition, and may beuseful for the prevention and treatment of conditions in mammals includinghumans, such as,diseases involving cartilage degradation, bone and/or joint degradation, forexample osteoarthritis；and/or conditions involving inflammation or immune responses, such as Crohn'sdisease, rheumatoidarthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis),juvenile idiopathic arthritis, colitis,inflammatory bowel diseases, endotoxin-driven disease states (e.g.complications after bypasssurgery or chronic endotoxin states contributing to e.g. chronic cardiacfailure), diseases involvingimpairment of cartilage turnover (e.g. diseases involving the anabolicstimulation of chondrocytes),congenital cartilage malformations, diseases associated with hypersecretion ofIL6 andtransplantation rejection (e.g. organ transplant rejection) and proliferativediseases.
